

ETHOS-PUSH: Hemoabdomen Study

PET OWNER'S GUIDE



ETHOS DISCOVERY

Ethos Discovery is a nonprofit incubator of scientific innovation. Our mission is to improve health outcomes for both human and pet patients with complex medical problems.

TABLE OF CONTENTS

01	INTRODUCTION	1
02	HEMOABDOMEN STUDY	2
03	HEMANGIOSARCOMA STUDY	3

To learn more about Ethos Discovery, please
visit our website ethosdiscovery.org



Your dog has been diagnosed with blood in the abdomen (hemoabdomen), believed to be related to a ruptured tumor on the spleen. As a result, he/she may be eligible to enroll in the Ethos Precision Medicine Umbrella Study for Hemangiosarcoma (Ethos-PUSH) trial.

ETHOS-PUSH IS A NEW CLINICAL STUDY INTENDED TO DELIVER THE BEST CARE POSSIBLE TO YOUR DOG.

THIS STUDY IS COMPOSED OF TWO PARTS:

- **Hemoabdomen Study:** This phase of the trial provides care for dogs around the treatment of their hemoabdomen, with surgical removal of the spleen (splenectomy).
- **Hemangiosarcoma Study:** Dogs subsequently diagnosed with splenic hemangiosarcoma (a common form of splenic cancer that can cause hemoabdomen) will be offered the option of continuing into this second phase of the trial. Dogs identified with other tumor types will not be eligible to participate in the second phase of the study.

Both phases of the study are reviewed in more detail below. All dogs enrolled in this study will contribute to improving outcomes for future patients diagnosed with hemoabdomen and hemangiosarcoma.

BY PARTICIPATING IN THIS STUDY YOUR DOG IS:

- RECEIVING THE BEST CARE AVAILABLE
- DELIVERING A CURE TO FUTURE DOGS
- IMPROVING OUTCOMES FOR HUMANS

HEMOABDOMEN STUDY

THIS IS THE LARGEST STUDY OF ITS KIND FOR DOGS WITH HEMOABDOMEN FROM A PRESUMED RUPTURED SPLENIC TUMOR WITHOUT EVIDENCE OF METASTASIS TO THE LUNGS. WE SEEK TO DELIVER HOPE TO FAMILIES WHOSE DOGS DEVELOP HEMOABDOMEN.

BENEFITS OF PARTICIPATING IN THIS STUDY:

- Your dog will receive the same state-of-the-art veterinary care as any of our patients.
- You will receive a \$1,000.00 credit to be applied to the cost of treatment for your dog's hemoabdomen at a participating Ethos Veterinary Health hospital.
- Blood and tumor samples collected through this study will support a nationwide collaborative research effort to better understand and treat canine hemangiosarcoma.

STUDY REQUIREMENTS

- Dogs will receive regular examinations for hemoabdomen and will have chest x-rays to ensure no evidence of cancerous spread (metastasis) to the lungs.
- A blood sample will be collected prior to your dog going to surgery. Efforts will be made to ensure this blood collection and standard pre-operative blood sample collections happen at the same time, so that there are no additional needle sticks needed.
- After successful removal of the spleen, small samples of the spleen and the associated tumor will be collected and saved for future analysis. Because these samples are being collected after removal from the body, it should not result in a longer surgical time or higher risk for complications.
- Dogs that are found to have hemangiosarcoma with no evidence of metastasis will be eligible to continue into the Hemangiosarcoma Study.

HEMANGIOSARCOMA STUDY

DOGS TREATED AS PART OF HEMOABDOMEN STUDY WHO ARE DIAGNOSED WITH SPLENIC HEMANGIOSARCOMA MAY BE ELIGIBLE TO CONTINUE ON TO THE HEMANGIOSARCOMA STUDY.

Based on previous studies conducted by our group, 40% of dogs with a ruptured splenic tumor will be diagnosed with benign disease that is cured with surgery alone. This rate of benign tumors is significantly higher than what has been previously reported from studies that used much less rigorous designs. Caution must be used when performing web searches about hemoabdomens, as many results will still quote the outdated low rate of benign tumors and not the current rate of 40%.

Our hemangiosarcoma study is evaluating novel treatments that seek to improve the long-term prognosis for dogs with this specific type of cancer. If your dog is eligible to continue, and you choose to enroll him or her, the cost of care for this portion of Ethos-PUSH will be fully covered by this study.

Following surgery we will determine whether continuation in the study is in the best interest of your dog. The hemangiosarcoma study seeks to deliver curative outcomes to dogs with hemangiosarcoma through the identification of the underlying genetic mutations that lead to cancer development and matching these with new drugs and drug combinations selected based on their ability to target these mutations.

THERE ARE NO PLACEBO TREATMENTS INCLUDED IN THE STUDY

ALL DOGS WILL RECEIVE ACTIVE DRUGS.

HEMOABDOMEN → HEMANGIOSARCOMA STUDY TIMELINE

Day 0

- Surgery
- Blood/tumor sample collection

3-5 Days Post-op

- Confirmation of tumor diagnosis
- If hemangiosarcoma, receive pet owner's guide for Hemangiosarcoma Study

7 Days Post-op

If hemangiosarcoma:

- Meet with oncologist
- Confirm eligibility for Hemangiosarcoma Study
- Continue care as directed by Oncologist

If not hemangiosarcoma:

- Discontinuation from study and follow doctor instructions

YOU AND YOUR DOG ARE HELPING CURE THIS DISEASE IN DOGS

This study is following a road map used to improve survival in childhood leukemia patients.

This road map starts with new knowledge and delivers the hope of this new knowledge through clinical trials to as many patients as possible.

Enrolling your eligible dog in this clinical trial will deliver the very best care that exists in veterinary oncology to your dog, and will provide the needed knowledge to cure this disease for future generations of canine patients.

**THE MISSION OF ETHOS DISCOVERY IS TO IMPROVE
HEALTH OUTCOMES FOR BOTH HUMAN AND PET
PATIENTS WITH COMPLEX MEDICAL PROBLEMS.**

A young girl with dark hair, wearing a grey knit sweater, is hugging a white dog. The dog is looking to the left with its mouth slightly open. The background is a soft, out-of-focus outdoor scene with warm lighting.

THANK YOU

A large, stylized graphic of a hexagon with a thick border, composed of two interlocking shapes. The word "ETHOS" is written in large, bold, white capital letters across the center, with "DISCOVERY" in smaller, white capital letters below it.

ETHOS

DISCOVERY

100% OF ALL DONATIONS SUPPORT SCIENTIFIC RESEARCH.